Business
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
Presented positive translational data from SYNGAP1-related disorders program showcasing efficacy ...
About this update from Canadian Goldcamps Corp
[{"type":"text","content":"CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights\n\n\n\n\n\n Presented positive translational data from SYNGAP1-related disorders program showcasing efficacy in a humanized SYNGAP mouse model and increased protein in non-human primates at the 28\n \n\n\n th\n \n\n\n American Society of Gene and Cell Therapy (ASGCT) Annual Meeting\n \n\n\n\n\n\n Initiating GLP toxicology studies evaluating CMP-SYNGAP-01 in Q3 2025\n \n\n\n\n\n\n Dosing completed in multiple ascending dose (MAD) cohort 3 of CMP-CPS-001 and data from single ascending dose (SAD) & MAD cohorts expected in Q4 2025\n \n\n\n\n\n CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) --\n \n CAMP4 Therapeutics Corporation\n \n (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update.\n \n\n “This past quarter, we presented compelling translational data from our SYNGAP1 program, reinforcing our confidence in CMP-SYGNAP-01's potential to transform the lives of patients living with this devastating neurological disorder, which currently has no approved treatments addressing the root cause,” said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. “With strong translational results and a clear unmet need, we remain committed to advancing CMP-SYNGAP-01 with urgency and are on track to initiate GLP toxicology studies in the third quarter, which could support initiation of a global Phase 1/2 clinical trial in SYNGAP patients in the second half of 2026.”\n \n\n Mr. Mandel-Brehm continued, “We continue to see strong potential in CMP-CPS-001 as a first-in-class, disease-modifying therapy for the most common UCDs and plan to announce safety and biomarker data from the SAD and MAD portions of the ongoing Phase 1 trial in healthy volunteers in Q4. These data could position CMP-CPS-001 as a valuable asset with an established safety profile that is ready for evaluation in symptomatic individuals, making it an ideal candidate for potential partnerships or further in-house development.&#...